Affomix, U Montreal PGx Centre, and Montreal Heart Institute Ink PGx Deal

Affomix and the PGx Centre will develop reagents for the quantitative multiplex profiling of candidate biomarkers that may allow clinicians to predict and evaluate how patients respond to novel anti-atherosclerotic agents.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.